Different animal models of pulmonary fibrosis have been developed to investigate potential
therapies for idiopathic pulmonary fibrosis (IPF). The most common is the bleomycin model …

Idiopathic pulmonary fibrosis (IPF) is one of a group of interstitial lung diseases that are
characterized by excessive matrix deposition and destruction of the normal lung …

This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American …

Background Idiopathic pulmonary fibrosis is a fatal disease for which no effective treatment
exists. We assessed whether treatment with interferon gamma-1b improved survival …

Objective The lack of randomized controlled trials (RCTs) in pulmonary fibrosis in systemic
sclerosis (SSc) has hampered an evidence‐based approach to treatment. This RCT was …

Rheumatoid arthritis (RA) is a destructive, systemic, inflammatory disorder that
characteristically affects small, diarthrodial joints in a progressive, symmetric, and erosive …

Background Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor
prognosis. Our objective is to assess the comparative effectiveness of 22 approved or …

Idiopathic pulmonary fibrosis (IPF) is the most common and most lethal diffuse fibrosing lung
disease, with a mortality rate that exceeds that of many cancers. Recently, there have been …

Colchicine (COL) has been used in medicine for a long time. It is well recognized as a valid
therapy in acute flares of gouty arthritis, familial Mediterranean fever (FMF), Behçet's …

1. INTRODUCTION 1.1 An overview of the ILD guideline Since the publication of the first
BTS guidelines for diffuse lung disease nearly 10years ago, 1 the specialty has seen …